Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Taranabant Loss No Surprise For Obesity Field, But Shock To Merck’s Pipeline

Executive Summary

Merck's widely expected decision to drop its Phase III obesity candidate taranabant places further doubt on the tainted cannabinoid-1 receptor antagonist class, but it also places doubt on Merck's near-term pipeline

You may also be interested in...



Pharma and Academia: Finding New Ways to Join Hands for Mutual Benefit

As Big Pharmas seek to hedge their development risk and look for more externally sourced programs, partnerships with academic institutions are one of the many ingredients in the R&D secret sauce. Such deals aren't the academic-industry tie-ups of yore-where Big Pharma sought small money partnerships without giving a lot back to their academic partners. Business development execs view them as yet another way to access critically important innovation.

How To Have A Winning R&D Strategy In Trying Times: An Interview With Merck Research Labs’ Gary Herman

Merck's 'fail fast' attitude toward R&D not only "more than pays for itself," it's "going to open up opportunities for us to do a lot more with our investment," Herman said.

Merck’s Heart Failure Drug Flunks Phase III

Rolofylline fails to meet primary and secondary endpoints in a Phase III trial.

Related Content

UsernamePublicRestriction

Register

PS050190

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel